# TSG Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/tsg-therapeutics

- Industry: Biotechnology
- Headquarters: Singapore
- Website: www.tsg-therapeutics.com
- Total disclosed funding: $5.6M
- Latest round: Series A (Dec 28, 2022)
- Investors on record: 6

## About

Based in Singapore, and founded in 2016, TSG Therapeutics operates as a preclinical-stage biopharmaceutical company that focuses on antiviral medicines to eliminate viral infectious diseases. The founder and the CEO of the company, Will Wonhyung Park, was the Managing Director and Head of the Strategic Investment Group at Deutsche Bank Group in Japan. Dr. Patricia Fast, the chief technology director, worked in National Institute of Allergy and Infectious Diseases. TSG Therapeutics has strategic cooperation with US National Institutes of Health, Vanderbilt University and other enterprises and universities.

The technologies developed by the company are Viral Envelope Targeting and Membrane-Active Agents. The technology forms the basis of novel broad-spectrum antiviral solutions with the potential to counter unpredictable viral threats. TSG is developing drug candidates that attack the lipid envelope target, demonstrating potent antiviral results against diverse classes of viruses.

## Funding rounds

- Series A, Dec 28, 2022, $5.6M — SparkLabs Global Ventures, Chiaphua Family Office, Mirae Asset Venture Investment, Daehan New Pharm Co., Ltd, Hanwha Pharma Co Ltd, NaturaLife Asia Co., Ltd

## Investors

- SparkLabs Global Ventures (https://capitalatlas.ai/funds/sparklabs-global-ventures) — Series A
- Chiaphua Family Office — Series A
- Mirae Asset Venture Investment (https://capitalatlas.ai/funds/mirae-asset-venture-investment) — Series A
- Daehan New Pharm Co., Ltd — Series A
- Hanwha Pharma Co Ltd — Series A
- NaturaLife Asia Co., Ltd — Series A